MedTrace Logo

Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation

NCT02399735 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-07-21

No results posted yet for this study

Summary

The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.

Conditions

Interventions

BIOLOGICAL

Low Dose NK cells ×4 times

Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.

BIOLOGICAL

Normal Dose NK cells ×4 times

Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.

BIOLOGICAL

Normal Dose NK cells ×8 times

Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Yang Yang, MD · Third Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02399735 on ClinicalTrials.gov